Skip to main content

Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ: TLSA). He gives his take on what the market can expect from the business this year, saying that it is now "moving forward quite nicely."

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.73
-2.49 (-1.02%)
AAPL  291.23
-10.31 (-3.42%)
AMD  470.01
-20.31 (-4.14%)
BAC  53.88
+0.25 (0.48%)
GOOG  358.69
-2.48 (-0.69%)
META  590.08
+4.69 (0.80%)
MSFT  403.01
-8.73 (-2.12%)
NVDA  205.00
-3.64 (-1.74%)
ORCL  205.03
-6.79 (-3.21%)
TSLA  394.98
-13.97 (-3.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.